FDA: Skin Reactions & TNF-a Inhibitors
Posted on: 3/24/08
In the FDA Drug Safety Newsletter for Winter, 2008, the agency states that safety reviews of the TNF-a Inhibitors, "infliximab (Remicade), etanercept (Enbrel), and adalimumab (Humira) identified rare cases of serious skin reactions."
The newsletter goes on to say that, "The presenting signs and symptoms of the serious skin reactions were mainly rash and skin lesions on the trunk, legs, arms, shoulder, back, hands, and face."
To read the entire statement from the FDA, please click here.
For more information on the TNF-a inhibitor class of medications, please see the following links:
|
STAY INFORMED!
Stay up-to-date on all the latest news and information regarding AS and related diseases with our news magazine, Spondylitis Plus. Your subscription comes free with SAA membership, so click here to join today!
|
|